- Home
- NAMS
as 01-21-2025 4:00pm EST
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
| Founded: | 2019 | Country: | Netherlands |
| Employees: | N/A | City: | NARRDEN |
| Market Cap: | 2.7B | IPO Year: | N/A |
| Target Price: | $38.17 | AVG Volume (30 days): | 538.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.19 - $27.29 | Next Earning Date: | 02-06-2025 |
| Revenue: | $33,594,000 | Revenue Growth: | 78.77% |
| Revenue Growth (this year): | 131.53% | Revenue Growth (next year): | -69.51% |
Latest NewAmsterdam Pharma Company N.V. News
NAMS Breaking Stock News: Dive into NAMS Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
GlobeNewswire
13 days ago
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
GlobeNewswire
a month ago
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Investor's Business Daily
a month ago
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
Investor's Business Daily
a month ago
NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug
GlobeNewswire
a month ago
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
GlobeNewswire
a month ago
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
Compare NAMS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NAMS NewAmsterdam Pharma Company N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.